THE DEAL, AT A GLANCE
From the announcementScorpion Therapeutics
01Who is involvedBacked by Foresite CapitalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedScorpion Therapeutics raised $200M Series CFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersScorpion Therapeutics is using its Series C financing to advance STX-478 through Phase 2 in PIK3CA-mutant breast cancer, positioning selectivity as the central clinical…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Scorpion Therapeutics · Financing Record
Explore source-linked visual explanations for Scorpion Therapeutics. Unsupported claims are withheld while source review continues.
Record 1307 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →